Recent update on the #Lassa vaccine study conducted by HJFMRI in Nigeria published in The Lancet. "The product is ready, and well kept. By the first quarter of next year, we will have completed our enrollment, meaning we'll have vaccinated all we need to vaccinate from Nigeria,” said Dr. ABDULWASIU BOLAJI TIAMIYU, Clinical Research Centre Director, HJFMRI Nigeria, and Principal Investigator for the #LassaVaccine trial in #Nigeria. IAVI; CEPI (Coalition for Epidemic Preparedness Innovations)
The Lancet Microbe recently published an update on the current #Lassafever outbreak in Nigeria. Here are the facts: ◾ The NCDC has reported 928 confirmed cases and 162 associated deaths as of June 30. ◾ The number of suspected cases has increased compared to the same period last year. Although no vaccine is currently available to manage the outbreak, a Phase 2 clinical trial is underway in Nigeria for IAVI's Lassa fever vaccine candidate. The candidate is built on the same rVSV vaccine vector technology as a licensed Ebola vaccine. Our Head of EIDs, Swati Gupta, emphasizes the promise of this technology – which is used across all IAVI EID vaccines. 📢 “The good thing about this particular technology and platform is that it works very quickly. We know that the immunity develops quite rapidly, and we also know that it only requires one dose..." Read the full article to hear from Gupta and Abdulwasiu Bolaji Tiamiyu, the principal investigator of the trial in Nigeria: https://lnkd.in/en9qp7pZ HJF Medical Research International | CEPI (Coalition for Epidemic Preparedness Innovations)